Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

Cytek Biosciences (NASDAQ:CTKB) reported third-quarter 2026 revenue of $53.2 million, up 2% from a year earlier, as growth in the U.S. and demand for its high-end instruments helped offset weakness in...

Cytek Biosciences Q3 Earnings Call Highlights ↗

November 04, 2026

Via MarketBeat

Performance

52-Week Range 13.3% below 52-week high

5.495

3.3152W Low 6.3352W High

1 Week 13.3% below 1-week high

5.671W Low 6.331W High

Cytek Biosciences, Inc. - Common Stock (CTKB) traded between $3.31 and $6.33 over the past 52 weeks and last traded at $5.50, 13.3% below its 52-week high. Over the past week it ranged between $5.67 and $6.33.

Past 12 Months

-12.8%

-9.8%

+31.5%

+11.2%

+11.7%

+40.5%

1W -$0.80

1M -$0.59

3M +$1.32

6M +$0.55

YTD +$0.58

1Y +$1.58

CTKB was +40.5% over the past year, +11.2% over six months, +11.7% year to date, -12.8% in the last week.

12 Months vs Market

CTKB

+40.5%

DIA

+9.6%

SPY

+9.2%

QQQ

+5.2%

IWM

+12.7%

Over the past 12 months CTKB returned +40.5% versus DIA (Dow) +9.6%, SPY (S&P 500) +9.2%, QQQ (Nasdaq 100) +5.2% and IWM (Russell 2000) +12.7%.

Volume & Liquidity 0.73× 3-mo avg

Today 897,551 3-mo avg 1.2M

1.6M

1.4M

1.2M

1.3M

YTD

1.1M

1.2M

CTKB most recently traded 897,551 shares against a 3-month average daily volume of 1.2M.

More News

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

September 23, 2026

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Cytek Biosciences Inc (NASDAQ:CTKB) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

September 23, 2026

Via Chartmill

September 09, 2026

From Cytek Biosciences, Inc.; Sysmex Europe SE

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

September 03, 2026

Cytek (CTKB) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

Cytek Biosciences Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

July 15, 2026

Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference

June 10, 2026

Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026

June 02, 2026

A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

May 13, 2026

From USA News Group

Cytek (CTKB) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact

March 09, 2026

Cytek (CTKB) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗

November 14, 2025

Via Benzinga

TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026

November 12, 2025

Cytek (CTKB) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

November 06, 2025

Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

October 29, 2025

Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth

October 15, 2025

Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA

September 10, 2025